Radionuclide Therapy for Liver Cancer
Author Information
Author(s): Felix Sundram
Primary Institution: Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Malaysia
Hypothesis
Radionuclide therapy can improve survival rates in patients with hepatocellular carcinoma (HCC) compared to traditional treatments.
Conclusion
Radionuclide therapy is a viable alternative to TACE for treating inoperable HCC, showing similar survival rates but better tolerance.
Supporting Evidence
- Radionuclide therapy showed a median survival of 54 weeks for inoperable HCC.
- Three-year survival rates were 86% for patients receiving adjuvant I-131 lipiodol therapy after curative resection.
- Yttrium-90 microspheres achieved an objective response rate of 80% in reducing serum α-fetoprotein levels.
Takeaway
Doctors can use special medicines that emit radiation to help treat liver cancer, which can work well and have fewer side effects than other treatments.
Methodology
The study involved administering various radionuclides via intra-arterial injection to patients with HCC and measuring their response and survival rates.
Potential Biases
Potential biases may arise from the non-randomized nature of some studies and the small sample sizes.
Limitations
The study may have limited generalizability due to the specific patient population and treatment protocols used.
Participant Demographics
Patients with inoperable hepatocellular carcinoma, including those with underlying cirrhosis.
Statistical Information
P-Value
null
Confidence Interval
null
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website